KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem–Like Cells and Promotes Metastasis
暂无分享,去创建一个
Kevin K. Chang | Soo-Jeong Cho | S. Ryeom | Sam S. Yoon | Chang-ming Huang | C. Yoon | Jacob E. Till | Jian‐xian Lin | Jian-Xian Lin
[1] Andrea Sottoriva,et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.
[2] Laura H. Tang,et al. Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. , 2017, Cancer research.
[3] R. Weinberg,et al. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.
[4] H. Hermeking,et al. Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations. , 2017, Cancer research.
[5] Hans Clevers,et al. CRISPR/Cas 9 genome editing and its applications in organoids. , 2017, American journal of physiology. Gastrointestinal and liver physiology.
[6] Ahmedin Jemal,et al. Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[7] R. Weinberg,et al. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. , 2015, Trends in cell biology.
[8] N. Schultz,et al. Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells , 2015, Clinical Cancer Research.
[9] P. Poulikakos,et al. Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.
[10] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[11] Michael Schumacher,et al. Modeling human development and disease in pluripotent stem cell-derived gastric organoids , 2014, Nature.
[12] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[13] A. Adjei,et al. The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.
[14] Hae-June Lee,et al. CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance , 2014, Clinical Cancer Research.
[15] M. Okada,et al. Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation , 2014, Oncotarget.
[16] I. Choi,et al. MicroRNA 135a Suppresses Lymph Node Metastasis through Down-Regulation of ROCK1 in Early Gastric Cancer , 2014, PloS one.
[17] T. Tan,et al. EMT-Induced Stemness and Tumorigenicity Are Fueled by the EGFR/Ras Pathway , 2013, PloS one.
[18] A. Wotherspoon,et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.
[19] Galina Kurteva,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.
[20] R. Weinberg,et al. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.
[21] L. Nicholson,et al. Cancer stem cells: in the line of fire. , 2012, Cancer treatment reviews.
[22] E. Chiorean. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .
[23] Y. Eishi,et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer , 2011, Gut.
[24] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[25] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[26] I. Bisson,et al. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.
[27] T. Wang,et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.
[28] J. Haerting,et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Ukcccr. UKCCCR Guidelines for the Use of Cell Lines in Cancer Research , 2000, British Journal of Cancer.
[30] T. Pawlik,et al. Mouse endostatin inhibits the formation of lung and liver metastases. , 1999, Cancer research.